Generic Tauvid Availability
Last updated on Jan 11, 2023.
TAUVID (flortaucipir f-18 - solution;intravenous)
Manufacturer: AVID RADIOPHARMS INC
Approval date: May 28, 2020
Strength(s): 30ML (8.1-51mCi/ML) [RLD], 50ML (8.1-51mCi/ML) [RLD]
Manufacturer: AVID RADIOPHARMS INC
Approval date: July 1, 2022
Strength(s): 50ML (8.1-100mCi/ML) [RLD], 100ML (8.1-100mCi/ML) [RLD]
Has a generic version of Tauvid been approved?
No. There is currently no therapeutically equivalent version of Tauvid available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tauvid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Imaging agents for detecting neurological dysfunction
Issued: January 13, 2015
Assignee(s): Eli Lilly and Company
Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.
Patent expiration dates:
- May 19, 2029✓
- May 19, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 28, 2025 - NEW CHEMICAL ENTITY
More about Tauvid (flortaucipir F 18)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.